RSeT™ Feeder-Free Medium
Serum-free medium for naïve-like human pluripotent stem cells
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to ƽ Technologies Canada Inc. and its subsidiaries and affiliates (“ƽ”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Ի.
This site is protected by reCAPTCHA and the Ի.
Overview
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Publications (1)
Effect of a FOXO1 inhibitor on trophoblast differentiation from human pluripotent stem cells and ERV-associated gene expression
Regenerative Therapy 2024 Sep
Abstract
IntroductionIn human placental development, the trophectoderm (TE) appears in blastocysts on day 5 post-fertilization and develops after implantation into three types of trophoblast lineages: cytotrophoblast (CT), syncytiotrophoblast (ST), and extravillous trophoblast (EVT). CDX2/Cdx2 is expressed in the TE, and Cdx2 expression is upregulated by knockdown of Foxo1 in mouse ESCs. However, the significance of FOXO1 in trophoblast lineage differentiation during the early developmental period remains unclear. In this study, we examined the effect of FOXO1 inhibition on the differentiation of naive human induced pluripotent stem cells (iPSCs) into TE and trophoblast lineages.MethodsWe induced TE differentiation from naive iPSCs in the presence or absence of a FOXO1 inhibitor, and the resulting cells were subjected to trophoblast differentiation procedures without the FOXO1 inhibitor. The cells obtained in these processes were assessed for morphology, gene expression, and hCG secretion using phase-contrast microscopy, reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR (RT-qPCR), RNA-seq, immunochromatography, and a chemiluminescent enzyme immunoassay.ResultsIn the induction of trophoblast differentiation from naive iPSCs, treatment with a FOXO1 inhibitor resulted in the enhanced expression of TE markers, CDX2 and HAND1, but conversely decreased the expression of ST markers, such as ERVW1 (Syncytin-1) and GCM1, and an EVT marker, HLA-G. The proportion of cells positive for an early TE marker TACSTD2 and negative for a late TE marker ENPEP was higher in FOXO1 inhibitor-treated cells than in non-treated cells. The expressions of ERVW1 (Syncytin-1), ERVFRD-1 (Syncytin-2), and other endogenous retrovirus (ERV)-associated genes that have been reported to be expressed in trophoblasts were suppressed in the cells obtained by differentiating the TE cells treated with FOXO1 inhibitor.ConclusionsTreatment with a FOXO1 inhibitor during TE induction from naive iPSCs promotes early TE differentiation but hinders the progression of differentiation into ST and EVT. The suppression of ERV-associated genes may be involved in this process. Highlights•Generated trophectoderm and trophoblast from feeder-free human naive iPS cells.•A FOXO1 inhibitor enhanced the expression of the trophectoderm marker CDX2.•Progression of differentiation into trophoblast was hindered by a FOXO1 inhibitor.•A FOXO1 inhibitor suppressed ERV-associated genes expressed in trophoblast.
Legal Statement:
Yeda Research and Development Ltd., an Israeli corporation (“YEDA”) is the owner of all right and title to certain patents applications and other proprietary rights which cover (i) the use of the product you are purchasing, such product comprising of media culture compositions to produce novel fully Naïve Induced Pluripotent Stem Cells (“iPSC’s”) (“the Product”) and (ii) the use of the iPSC’s themselves. By purchase of the Product, you shall have, subject to the terms of use below, a limited non-exclusive licence to use the Products to generate iPSC’s and the iPSC’s themselves. YOU HEREBY AGREE TO USE THE PRODUCT AND ANY RESULTS OR PHYSICAL MATTER, INCLUDING IPSC’S, GENERATED FROM THE USE OF THE PRODUCT, OR ANY COPIES OR DERIVATIVES OF ANY OF THE FOREGOING, SOLELY FOR THE PURPOSE OF CONDUCTING NON-COMMERCIAL RESEARCH ACTIVITIES AND PUBLISHING THE RESULTS OF SUCH ACTIVITIES. YOU HEREBY ACKNOWLEDGE THAT ANY USE THEREOF FOR PURPOSES OTHER THAN NON-COMMERCIAL RESEARCH AND PUBLICATION IS PROHIBITED AND SHALL BE PROSECUTED TO THE FULL EXTENT OF THE LAW. IN THE EVENT YOU WISH TO USE THE ABOVE FOR ANY OTHER PURPOSE, A SEPARATE LICENSE IS REQUIRED. YOU CAN CONTACT YEDA AT INFO.YEDA@WEIZMANN.AC.IL FOR THE PURPOSE OF OBTAINING A SEPARATE LICENCE IN THIS REGARD, YEDA BEING IN NO WAY OBLIGATED TO ENTER INTO OR NEGOTIATE SUCH A LICENCE WITH YOU. Nothing contained herein shall be deemed to be a representation or warranty, express or implied, by YEDA that patent applications relating to the Product and the iPSC’s will be granted; (ii) that patents obtained on any of the said patent applications are or will be valid or will afford proper protection; (iii) that the use of the Product or the iPSC’s will not infringe the rights of any third party; or (iv) as to the potential, use, exploitability, merchantability, suitability, effectiveness, fitness for purpose or safety of the Product and the iPSC’s.Under no circumstances shall YEDA be liable for any claims, demands, liabilities, costs, losses, damages or expenses (including legal costs and attorney's fees) of whatever kind (any of the above, a “Loss”) caused to or suffered by any person or entity that directly or indirectly arise out of the use of the Product or the iPSC’s. Copyright © 2017 ƽ Inc. All rights reserved including graphics and images. ƽ Technologies & Design, ƽ Shield Design, Scientists Helping Scientists, STEMdiff, and RSeT are trademarks of ƽ Technologies Canada Inc. mTeSR is a trademark of WARF. All other trademarks are the property of their respective holders. While ƽ has made all reasonable efforts to ensure that the information provided by ƽ and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.
Yeda Research and Development Ltd., an Israeli corporation (“YEDA”) is the owner of all right and title to certain patents applications and other proprietary rights which cover (i) the use of the product you are purchasing, such product comprising of media culture compositions to produce novel fully Naïve Induced Pluripotent Stem Cells (“iPSC’s”) (“the Product”) and (ii) the use of the iPSC’s themselves. By purchase of the Product, you shall have, subject to the terms of use below, a limited non-exclusive licence to use the Products to generate iPSC’s and the iPSC’s themselves. YOU HEREBY AGREE TO USE THE PRODUCT AND ANY RESULTS OR PHYSICAL MATTER, INCLUDING IPSC’S, GENERATED FROM THE USE OF THE PRODUCT, OR ANY COPIES OR DERIVATIVES OF ANY OF THE FOREGOING, SOLELY FOR THE PURPOSE OF CONDUCTING NON-COMMERCIAL RESEARCH ACTIVITIES AND PUBLISHING THE RESULTS OF SUCH ACTIVITIES. YOU HEREBY ACKNOWLEDGE THAT ANY USE THEREOF FOR PURPOSES OTHER THAN NON-COMMERCIAL RESEARCH AND PUBLICATION IS PROHIBITED AND SHALL BE PROSECUTED TO THE FULL EXTENT OF THE LAW. IN THE EVENT YOU WISH TO USE THE ABOVE FOR ANY OTHER PURPOSE, A SEPARATE LICENSE IS REQUIRED. YOU CAN CONTACT YEDA AT INFO.YEDA@WEIZMANN.AC.IL FOR THE PURPOSE OF OBTAINING A SEPARATE LICENCE IN THIS REGARD, YEDA BEING IN NO WAY OBLIGATED TO ENTER INTO OR NEGOTIATE SUCH A LICENCE WITH YOU. Nothing contained herein shall be deemed to be a representation or warranty, express or implied, by YEDA that patent applications relating to the Product and the iPSC’s will be granted; (ii) that patents obtained on any of the said patent applications are or will be valid or will afford proper protection; (iii) that the use of the Product or the iPSC’s will not infringe the rights of any third party; or (iv) as to the potential, use, exploitability, merchantability, suitability, effectiveness, fitness for purpose or safety of the Product and the iPSC’s.Under no circumstances shall YEDA be liable for any claims, demands, liabilities, costs, losses, damages or expenses (including legal costs and attorney's fees) of whatever kind (any of the above, a “Loss”) caused to or suffered by any person or entity that directly or indirectly arise out of the use of the Product or the iPSC’s. Copyright © 2017 ƽ Inc. All rights reserved including graphics and images. ƽ Technologies & Design, ƽ Shield Design, Scientists Helping Scientists, STEMdiff, and RSeT are trademarks of ƽ Technologies Canada Inc. mTeSR is a trademark of WARF. All other trademarks are the property of their respective holders. While ƽ has made all reasonable efforts to ensure that the information provided by ƽ and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ƽ, REFER TO WWW.ƽ.COM/COMPLIANCE.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ƽ, REFER TO WWW.ƽ.COM/COMPLIANCE.
Safety Statement:
CA WARNING: This product can expose you to Progesterone which is known to the State of California to cause cancer. For more information go to
